Literature DB >> 16687925

The basal phenotype of BRCA1-related breast cancer: past, present and future.

Marc D Tischkowitz1, William D Foulkes.   

Abstract

Many BRCA1-related tumors have a distinct histological characteristics which together have been called "basal-like." Typically such tumors are ER-, HER2- and express cytokeratin 5/6, cytokeratin 8/18, EGFR and vimentin. These characteristics can be used to predict which breast cancers are most likely to be associated with germline BRCA1 mutations which has important implications for breast pathologists. Moreover, BRCA1-related breast cancers generally have a poorer prognosis which may paradoxically be more pronounced in node negative cancers. This may relate in part to a different pattern of metastatic spread with in increased frequency of brain and lung metastases in BRCA1 carriers. Conversely, BRCA1-related tumors may respond better to neoadjuvant chemotherapy and their characteristic molecular signature may provide opportunities to develop specific molecular targeted therapies akin to traztuzumab in HER2+ cancers. Finally, many of the phenotypic features of BRCA1-related tumors might also be found in putative breast stem cells and therefore characterization of the BRCA1 breast cancer phenotype will improve our understanding of sporadic breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687925     DOI: 10.4161/cc.5.9.2713

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.

Authors:  Gayatri Sharma; Sameer Mirza; Rajinder Parshad; Siddartha Datta Gupta; Ranju Ralhan
Journal:  Tumour Biol       Date:  2012-06-29

2.  Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.

Authors:  Feng Qi; Wen-Xing Qin; Yuan-Sheng Zang
Journal:  Oncol Lett       Date:  2019-01-03       Impact factor: 2.967

3.  p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.

Authors:  Fanyan Meng; Haijun Zhang; Gang Liu; Bas Kreike; Wei Chen; Seema Sethi; Fred R Miller; Guojun Wu
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

4.  P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.

Authors:  Joana Paredes; Nair Lopes; Fernanda Milanezi; Fernando C Schmitt
Journal:  Virchows Arch       Date:  2006-11-23       Impact factor: 4.064

5.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

Review 6.  DNA double-strand break repair pathway choice and cancer.

Authors:  Tomas Aparicio; Richard Baer; Jean Gautier
Journal:  DNA Repair (Amst)       Date:  2014-04-18

7.  The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.

Authors:  Reena Shakya; Matthias Szabolcs; Ellen McCarthy; Elson Ospina; Katia Basso; Subhadra Nandula; Vundavalli Murty; Richard Baer; Thomas Ludwig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

8.  Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.

Authors:  GianMaria Miolo; Vincenzo Canzonieri; Clelia De Giacomi; Lara Della Puppa; Riccardo Dolcetti; Davide Lombardi; Tiziana Perin; Simona Scalone; Andrea Veronesi; Alessandra Viel
Journal:  BMC Cancer       Date:  2009-10-10       Impact factor: 4.430

9.  Recent trends in breast cancer among younger women in the United States.

Authors:  Louise A Brinton; Mark E Sherman; J Daniel Carreon; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2008-11-11       Impact factor: 13.506

10.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

Authors:  N Turner; M B Lambros; H M Horlings; A Pearson; R Sharpe; R Natrajan; F C Geyer; M van Kouwenhove; B Kreike; A Mackay; A Ashworth; M J van de Vijver; J S Reis-Filho
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.